December ETH Price Prediction · Posting Challenge 📈
With rate-cut expectations heating up in December, ETH sentiment turns bullish again.
We’re opening a prediction challenge — Spot the trend · Call the market · Win rewards 💰
Reward 🎁:
From all correct predictions, 5 winners will be randomly selected — 10 USDT each
Deadline 📅: December 11, 12:00 (UTC+8)
How to join ✍️:
Post your ETH price prediction on Gate Square, clearly stating a price range
(e.g. $3,200–$3,400, range must be < $200) and include the hashtag #ETHDecPrediction
Post Examples 👇
Example ①: #ETHDecPrediction Range: $3,150–
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.